We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Germany Dedicates Billions to Healthcare Research

By LabMedica International staff writers
Posted on 20 Sep 2011
Germany has allocated over EUR 5.5 billion in federal grants to support healthcare research over the next four years. The country trails only the United States in biopharmaceutical production, with this new program providing a boost to bringing research results quickly to market.

Germany Trade & Invest (Berlin) had biotechnology industry experts combined with a business delegation at the 2011 Biopharm America from September 7-9, 2011, in Boston, MA, USA, to share the latest business and partnering opportunities in Germany.

“Germany is already known as an established player in the pharmaceutical industry. A wealth of innovative small and medium enterprises and excellent opportunities for research partnerships are helping the country maintain its edge,” stated Gabriel Flemming, medical biotechnology expert at Germany Trade & Invest.

For years, the combination of policymaking, research, and development (R&D), venture capital, and industry initiatives have taken Germany’s industry in a new direction. With an emphasis on biotechnology, the industry is becoming increasingly sustainable while finding innovative ways to tackle public health challenges.

“Germany is especially making progress in the field of personalized medicine,” continued Mr. Flemming. “Foreign companies and venture capitalists are drawn to German biotechnology clusters, as diagnostics firms are working closely with the biopharmaceutical industry to create innovation hotbeds across the country.”

Biotechnology regions can qualify for additional grants from the federal government. BioM (Munich, Germany), for example, received millions for its work in personalized medicine. Dr. Horst Domdey, managing director of BioM, joined the Germany Trade & Invest delegation and informed companies of the partnering and investment possibilities in this cluster.

Germany Trade & Invest is the foreign trade and inward investment promotion agency of the Federal Republic of Germany. It provides information on foreign trade to German companies that seek to enter foreign markets.

Related Links:

Germany Trade & Invest



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Automated Urinalysis Solution
UN-9000

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
20 Sep 2011  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
20 Sep 2011  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
20 Sep 2011  |   BioResearch